Stifel Financial Corp Purchases 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Stifel Financial Corp raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 30.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,967 shares of the biotechnology company's stock after acquiring an additional 20,546 shares during the period. Stifel Financial Corp owned about 0.08% of Corcept Therapeutics worth $4,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hancock Whitney Corp boosted its stake in shares of Corcept Therapeutics by 1.2% during the third quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company's stock valued at $1,062,000 after purchasing an additional 270 shares during the period. KBC Group NV lifted its holdings in Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company's stock worth $131,000 after buying an additional 496 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Corcept Therapeutics by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,368 shares of the biotechnology company's stock worth $174,000 after buying an additional 510 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in shares of Corcept Therapeutics during the third quarter valued at approximately $25,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in Corcept Therapeutics by 0.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 127,348 shares of the biotechnology company's stock worth $4,138,000 after acquiring an additional 541 shares during the period. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Stock Up 0.1 %

Corcept Therapeutics stock traded up $0.03 during trading hours on Monday, hitting $55.43. The stock had a trading volume of 856,095 shares, compared to its average volume of 1,155,995. The stock's 50-day moving average price is $53.28 and its 200-day moving average price is $41.46. The stock has a market capitalization of $5.81 billion, a P/E ratio of 43.99 and a beta of 0.51. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $62.22. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same period in the previous year, the business earned $0.28 EPS. The firm's revenue for the quarter was up 47.7% on a year-over-year basis. Equities research analysts anticipate that Corcept Therapeutics Incorporated will post 1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Truist Financial raised their target price on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the stock a "buy" rating in a research report on Monday, September 30th. Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an "overweight" rating in a report on Wednesday, September 18th. Sandler O'Neill reissued a "buy" rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. StockNews.com lowered shares of Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 25th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $65.25.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the completion of the transaction, the insider now owns 8,494 shares in the company, valued at $481,779.68. This trade represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,811 shares of company stock worth $1,341,360 over the last three months. 20.50% of the stock is currently owned by company insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.